SLC5A2 and myocardial infarction: Sodium-glucose cotransporter-2 inhibitors have shown class-effect signals in improving morphological features of plaque vulnerability in early noninvasive and invasive imaging studies; however, these findings are limited by their observational nature.87 Concurrently, randomized clinical trial data on glucagon-like peptide-1 receptor agonists are accumulating, demonstrating cardiovascular benefits, particularly in reducing myocardial infarction.88 The role of these novel compounds in plaque modification warrants dedicated investigation.